ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Arno Therapeutics Inc (CE)

Arno Therapeutics Inc (CE) (ARNI)

0.0001
0.00
( 0.00% )
Updated: 18:00:00

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.0001
Bid
0.00
Ask
0.00
Volume
-
0.00 Day's Range 0.00
0.000058 52 Week Range 0.0003
Previous Close
0.0001
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
14,983
Financial Volume
-
VWAP
-

ARNI Latest News

Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief...

FLEMINGTON, N.J., July 18, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

FLEMINGTON, N.J., May 29, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics Reports First Quarter 2014 Financial and Business Update

FLEMINGTON, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men's and Women's Cancers at 2014 ASCO Annual Meet...

Studies to determine recommended Phase II dose and safety profile of lead compound Will analyze relationship of biomarker to any anti-tumor activity observed FLEMINGTON, N.J., May 14, 2014...

Arno Therapeutics Announces Clinical Abstracts Accepted at 2014 ASCO Annual Meeting

FLEMINGTON, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistan...

FLEMINGTON, N.J., April 7, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones

FLEMINGTON, N.J., April 1, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014...

FLEMINGTON, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics Board of Directors Appoints Randy Thurman as Vice Chairman

FLEMINGTON, N.J., March 24, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

Arno Therapeutics to Present at 26th Annual ROTH Conference

FLEMINGTON, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
12000.00010.00010.0001149830.0001CS
26-0.0002-66.66666666670.00030.00030.000174920.0001CS
524.2E-572.41379310345.8E-50.00035.8E-537570.00012027CS
156-0.002-95.23809523810.00210.00211.0E-666027.33E-5CS
260-0.0017-94.44444444440.00180.0421.0E-6649900.00488503CS

ARNI - Frequently Asked Questions (FAQ)

What is the current Arno Therapeutics (CE) share price?
The current share price of Arno Therapeutics (CE) is US$ 0.0001
What is the 1 year trading range for Arno Therapeutics (CE) share price?
Arno Therapeutics (CE) has traded in the range of US$ 0.000058 to US$ 0.0003 during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ELIQQElectriq Power Holdings Inc (CE)
US$ 0.10
(99,900.00%)
100
HAVLFHavn Life Sciences Inc (CE)
US$ 0.001
(99,900.00%)
10.12k
STTOSITO Mobile Ltd (CE)
US$ 0.0012
(59,900.00%)
500
SIRCSolar Integrated Roofing Corporation (PK)
US$ 0.0002
(19,900.00%)
5.19M
LLBOLifeline Biotech Inc (CE)
US$ 0.0002
(19,900.00%)
10k
NOKPFNok Airlines Public Company Ltd (CE)
US$ 0.0001
(-99.75%)
154.79k
NEOMNeoMedia Technologies Inc (CE)
US$ 0.000001
(-99.50%)
50.34k
IFANIFAN Financial Inc (CE)
US$ 0.000001
(-99.50%)
104k
PLPLPlandai Biotechnology Inc (PK)
US$ 0.000001
(-99.00%)
1.36M
MAPTMAPtelligent Inc (CE)
US$ 0.000001
(-99.00%)
165k
PHILPHI Group Inc (PK)
US$ 0.0005
(66.67%)
263.16M
HMBLHUMBL Inc (PK)
US$ 0.0008
(0.00%)
158.86M
RDARRaadr Inc (PK)
US$ 0.0015
(11.11%)
104.7M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0002
(100.00%)
59.02M
GTCHGBT Technologies Inc (PK)
US$ 0.0002
(0.00%)
36.01M

Discussion

View Full Feed
WorstLuck WorstLuck 2 minutes ago
I don't understand how going to the patent office would help, as they would have to correct the 048 to C1-C12 IMHO. Correcting 953 to C2-C12 wouldn't help as they would have no claim against C1. That correction would have had to have been made before 953 was filed to supersede it???

Grey_Ghost Grey_Ghost 2 minutes ago
Same Yorkville Advisors? https://www.forbes.com/sites/nathanvardi/2012/10/17/sec-charges-formerly-1-billion-yorkville-advisors-hedge-fund-with-fraud-and-bogus-valuations/
NWBO
Risk vs Reward Risk vs Reward 2 minutes ago
Damn !!! Most respect to you 
KULR
tedpeele tedpeele 2 minutes ago
Better modulators have a place - very possibly with Global Foundries, just as Lightmatter does.

And it is possible they can have a significant place within the modulator device world.

But there are many other technologies out there - including other photonic technologi
LWLG
LowFloatLopes LowFloatLopes 2 minutes ago
Private investors are buying the company out
LILMF
DiscoverGold DiscoverGold 2 minutes ago
$NVDA Top Bearish Flow – Open...
By: Peter DiCarlo | December 26, 2024

• Top Bearish Flow – Open

TSLA – $22.78M
NVDA – $11.11M
AAPL – $3.75M
META – $1.33M
MSTR – $1.23M

pbs.twimg.com/media/GfvBYNvWkAARD9R?
AAPL MSTR NVDA
doc2016 doc2016 2 minutes ago
geminia ai pro says:"carrier frequency and teleportation




You're thinking in a very creative and abstract way! While carrier frequency and teleportation might seem unrelated at first glance, there are some intriguing connections and potential parallels, particu
IONQ
Jack_of_All_Trades Jack_of_All_Trades 3 minutes ago
RDAR looks ready to run on heavy volume...
RDAR
Golden Cross Golden Cross 3 minutes ago
$ILLR Upcoming announcement of the biggest combat championship in the world.
ILLR
DiscoverGold DiscoverGold 3 minutes ago
$AMD Top Bearish Flow – Open...
By: Peter DiCarlo | December 26, 2024

• Top Bearish Flow – Open

TSLA – $22.78M
NVDA – $11.11M
AAPL – $3.75M
META – $1.33M
MSTR – $1.23M

pbs.twimg.com/media/GfvBYNvWkAARD9R?f
AAPL AMD MSTR
found_it2 found_it2 3 minutes ago
"Short-Squeeze Target Anavex Life Sciences Gains Traction"
Story by Thomas Hughes, MarketBeat • 3h

Anavex Life Sciences (NASDAQ: AVXL) is a short-squeeze candidate because its share prices are rising on good news, institutional and analyst support is growing, and the short-sell
AVXL
doc2016 doc2016 3 minutes ago
carrier frequency and teleportation




You're thinking in a very creative and abstract way! While carrier frequency and teleportation might seem unrelated at first glance, there are some intriguing connections and potential parallels, particularly when we conside
dstock07734 dstock07734 3 minutes ago
Did you really read hundreds of papers related to DCVax-L? The other day a self-claimed Ph.D. in biochemistry wrote a hit piece which is full of nonsense.

If you read so many papers, you should have known what exactly makes DCVax-L so unique and amazing and you should have known that
NWBO
tw0122 tw0122 3 minutes ago
$10.80 on the way to $12 again target 
WKEY
HGilS HGilS 3 minutes ago
We are on target to have another great year. We are on target to skip the sixties and go for the seventies. This is going to be another record breaking year for us. Our growth cycle continues and it will be even stronger starting in calendar year 2025 and beyond. Our stock price now reflects our cur
ELTP
BreakingNews1 BreakingNews1 3 minutes ago
Very Bullish 2025 RDAR

#1 2025 Stock To Buy Before 12/31/24. #Stocks #StockMarket $RDAR s Compound Annual Growth Rate Projected To Skyrocket $700 Mill. Euros in 2027 equals $728,423,068. Mill. USD
RDAR
bas2020 bas2020 3 minutes ago
NWBO now has $50M backstop giving them a longer runway to automated production and strong revenue generation. There's no "bending over backwards." LP will be in control of partnership negotiations, holding what she holds.
NWBO
Jack_of_All_Trades Jack_of_All_Trades 3 minutes ago
RDAR looks ready to run on heavy volume...
RDAR
gdog gdog 4 minutes ago
12-26 B EDIT $1.17
theorysuit theorysuit 4 minutes ago
BP provides their drug in a lot of trials. NWBO on the other hand can't even supply their own drug. That's why NWBO can't even PR what UCLA is doing because it isn't NWBO who is providing it. There will be no PR/investment from BP on anything related to NWBO.
NWBO
Motor-goater Motor-goater 4 minutes ago
Ho …. The answer to your missing financials from 2016 and 2017 can easily be found in a quick skim through of the company history. You are spreading false information. Why are you doing this?
CNNA
Golden Cross Golden Cross 4 minutes ago
$ILLR Upcoming announcement of the biggest combat championship in the world
ILLR
Rambo Rell Rambo Rell 4 minutes ago
$ILLR Strategic Partnerships
🤝 Building alliances: Recent partnerships with industry leaders will drive adoption, increase visibility, and solidify the company’s position in the market.
ILLR
skeptic7 skeptic7 4 minutes ago
In order for them to be correct, it stands to reason that the first in line should fall into place. The first "prediction" is a release on January 20th. Well, I hate to be the bearer of bad news, but there will be NO release on that date, and likely not this year.
FNMA
KnowNothingJonSnow KnowNothingJonSnow 4 minutes ago
San Diego Living is the new Larry Bird Legend it seems.
AMRN

Your Recent History

Delayed Upgrade Clock